hypertrophic cardiomyopathy
Advertisement
Researchers found that the oral myosin inhibitor, mavacamten, significantly reduced the proportion of patients with ...
The United States Food and Drug Administration (FDA) approved Mavacamten to treat patients with symptomatic obstructive ...
In this insightful interview, Rawan Amir, MBBS, and CardioNerds Academy Fellow, spoke with Milind Desai, MD, MBA, ...
As novel therapeutic agents such as Mavacamten and Tafamidis are developed and become clinically useful for patients ...
VALOR-HCM: Mavacamten Decreases Need for Septal Reduction Therapy in Symptomatic Obstructive HCM
...
New pharmacological agent reduces need for septal reduction therapy in patients with symptomatic obstructive ...
This week's edition includes the question of whether guideline recommendations for family early screening for ...
A new study suggests that early screening guidelines for phenotype-positive hypertrophic cardiomyopathy (HCM) may be ...
The findings of a recent study which appeared in JAMA Cardiology suggest obesity is a problem among patients with ...
Researchers have recently developed an artificial intelligence (AI) classifier that can detect a specific cardiovascular ...
Whole genome sequencing (WGS) was able to identify additional genetic causes of hypertrophic cardiomyopathy (HCM) when ...
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.